Mary V. Relling

63.5k total citations · 19 hit papers
381 papers, 33.5k citations indexed

About

Mary V. Relling is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Mary V. Relling has authored 381 papers receiving a total of 33.5k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Public Health, Environmental and Occupational Health, 191 papers in Pediatrics, Perinatology and Child Health and 90 papers in Molecular Biology. Recurrent topics in Mary V. Relling's work include Acute Lymphoblastic Leukemia research (230 papers), Childhood Cancer Survivors' Quality of Life (137 papers) and Pharmacogenetics and Drug Metabolism (63 papers). Mary V. Relling is often cited by papers focused on Acute Lymphoblastic Leukemia research (230 papers), Childhood Cancer Survivors' Quality of Life (137 papers) and Pharmacogenetics and Drug Metabolism (63 papers). Mary V. Relling collaborates with scholars based in United States, Germany and Netherlands. Mary V. Relling's co-authors include William E. Evans, Ching‐Hon Pui, James R. Downing, John T. Sandlund, Wenjian Yang, Gaston K. Rivera, John D. Schuetz, Cheng Cheng, Raul C. Ribeiro and Erin G. Schuetz and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mary V. Relling

372 papers receiving 32.7k citations

Hit Papers

Pharmacogenomics: Translating Functional Genomics into Ra... 1997 2026 2006 2016 1999 2001 2007 2004 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
    1999 1.8k citations William E. Evans, Mary V. Relling profile →
  2. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
    2001 1.8k citations John D. Schuetz, Mary V. Relling et al. profile →
  3. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
    2007 1.2k citations Charles G. Mullighan, Elaine Coustan‐Smith et al. profile →
  4. Acute Lymphoblastic Leukemia
    2004 850 citations Ching‐Hon Pui, Mary V. Relling et al. profile →
  5. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
    2008 711 citations Charles G. Mullighan, Ching‐Hon Pui et al. profile →
  6. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
    2015 592 citations Ching‐Hon Pui, Jun J. Yang et al. Journal of Clinical Oncology profile →
  7. Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance
    1997 583 citations Mary V. Relling et al. profile →
  8. Pharmacogenomics in the clinic
    2015 554 citations Mary V. Relling, William E. Evans profile →
  9. Moving towards individualized medicine with pharmacogenomics
    2004 510 citations William E. Evans, Mary V. Relling profile →
  10. Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus
    1999 495 citations Mary V. Relling, John T. Sandlund et al. profile →
  11. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
    2018 403 citations Mary V. Relling, Matthias Schwab et al. Clinical Pharmacology & Therapeutics profile →
  12. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
    2011 401 citations Mary V. Relling, William E. Evans et al. Clinical Pharmacology & Therapeutics profile →
  13. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
    2012 374 citations Ching‐Hon Pui, Charles G. Mullighan et al. Blood profile →
  14. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
    2019 369 citations Cyrine E. Haidar, Teri E. Klein et al. profile →
  15. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
    2016 354 citations Teri E. Klein, Mary V. Relling et al. profile →
  16. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
    2014 345 citations Kristine R. Crews, James M. Hoffman et al. profile →
  17. Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia
    2015 306 citations Jun J. Yang, Wendy Landier et al. Journal of Clinical Oncology profile →
  18. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized
    2018 246 citations Mary V. Relling et al. profile →
  19. Pharmacogenomics
    2019 238 citations Howard L. McLeod, Mary V. Relling et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary V. Relling United States 97 14.5k 12.3k 8.6k 7.6k 7.4k 381 33.5k
William E. Evans United States 93 15.6k 1.1× 11.3k 0.9× 9.4k 1.1× 6.7k 0.9× 5.8k 0.8× 386 34.0k
Ching‐Hon Pui United States 110 26.0k 1.8× 16.7k 1.4× 10.5k 1.2× 8.6k 1.1× 1.0k 0.1× 629 45.5k
Teri E. Klein United States 86 2.4k 0.2× 6.3k 0.5× 7.2k 0.8× 4.8k 0.6× 12.8k 1.7× 362 30.2k
Munir Pirmohamed United Kingdom 88 1.5k 0.1× 5.3k 0.4× 6.1k 0.7× 4.0k 0.5× 8.6k 1.2× 601 34.5k
Howard L. McLeod United States 81 1.9k 0.1× 2.6k 0.2× 9.6k 1.1× 10.1k 1.3× 6.6k 0.9× 481 26.6k
Jan H.M. Schellens Netherlands 91 1.3k 0.1× 3.2k 0.3× 16.1k 1.9× 22.6k 3.0× 3.6k 0.5× 882 41.1k
Alex Sparreboom United States 86 1.1k 0.1× 3.3k 0.3× 8.9k 1.0× 14.2k 1.9× 3.3k 0.4× 408 24.4k
Charles L. Loprinzi United States 91 2.2k 0.2× 2.1k 0.2× 3.6k 0.4× 15.5k 2.0× 1.1k 0.1× 531 33.3k
Mark J. Ratain United States 74 1.6k 0.1× 2.1k 0.2× 9.1k 1.1× 10.2k 1.3× 2.8k 0.4× 532 23.0k
Henk‐Jan Guchelaar Netherlands 63 1.2k 0.1× 1.9k 0.2× 4.1k 0.5× 4.6k 0.6× 3.7k 0.5× 452 15.7k

Countries citing papers authored by Mary V. Relling

Since Specialization
Citations

This map shows the geographic impact of Mary V. Relling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary V. Relling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary V. Relling more than expected).

Fields of papers citing papers by Mary V. Relling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary V. Relling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary V. Relling. The network helps show where Mary V. Relling may publish in the future.

Co-authorship network of co-authors of Mary V. Relling

This figure shows the co-authorship network connecting the top 25 collaborators of Mary V. Relling. A scholar is included among the top collaborators of Mary V. Relling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary V. Relling. Mary V. Relling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pauley, Jennifer L., John C. Panetta, Deqing Pei, et al.. (2016). Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. Journal of Pediatric Hematology/Oncology. 38(6). 449–452. 15 indexed citations
3.
Gammal, Roseann S., Kristine R. Crews, Cyrine E. Haidar, et al.. (2016). Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. PEDIATRICS. 138(1). 56 indexed citations
4.
Bhojwani, Deepa, Noah D. Sabin, Deqing Pei, et al.. (2014). Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(9). 949–959. 242 indexed citations
5.
Roberts, Kathryn G., Deqing Pei, Dario Campana, et al.. (2014). Outcomes of Children With BCR-ABL1 –Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology. 32(27). 3012–3020. 165 indexed citations
6.
Tong, Wing H., Rob Pieters, Gertjan J.L. Kaspers, et al.. (2014). A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 123(13). 2026–2033. 155 indexed citations
7.
Bhatia, Ravi, Wendy Landier, Lindsey Hageman, et al.. (2014). 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 124(15). 2345–2353. 152 indexed citations
8.
9.
Bhatia, Smita, Wendy Landier, Lindsey Hageman, et al.. (2012). Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(17). 2094–2101. 243 indexed citations
10.
Ramsey, Laura B., John C. Panetta, Colton Smith, et al.. (2012). Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6). 898–904. 157 indexed citations
11.
Ciarimboli, Giuliano, Cynthia S. Lancaster, Eberhard Schlatter, et al.. (2012). Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients. Clinical Cancer Research. 18(4). 1101–1108. 125 indexed citations
12.
Blanco, Javier G., Can-Lan Sun, Wendy Landier, et al.. (2011). Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(13). 1415–1421. 269 indexed citations
13.
Kawedia, Jitesh D., Sue C. Kaste, Deqing Pei, et al.. (2010). Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 117(8). 2340–2347. 186 indexed citations
14.
Yang, Jun J., Erin G. Schuetz, Mark J. Ratain, et al.. (2009). Etoposide pathway. Pharmacogenetics and Genomics. 19(7). 552–553. 40 indexed citations
15.
Innocenti, Federico, Deanna L. Kroetz, Erin G. Schuetz, et al.. (2009). Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics. Journal of Clinical Oncology. 27(16). 2604–2614. 200 indexed citations
16.
Yang, Lei, John C. Panetta, Xiangjun Cai, et al.. (2008). Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 26(12). 1932–1939. 107 indexed citations
17.
Krishnamurthy, Partha, Matthias Schwab, Kazumasa Takenaka, et al.. (2008). Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research. 68(13). 4983–4989. 116 indexed citations
18.
Jones, Terreia S., Sue C. Kaste, Wei Liu, et al.. (2008). CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 26(18). 3031–3037. 36 indexed citations
19.
Jones, Terreia S., Wentao Yang, William E. Evans, & Mary V. Relling. (2007). Using HapMap Tools in Pharmacogenomic Discovery: The Thiopurine Methyltransferase Polymorphism. Clinical Pharmacology & Therapeutics. 81(5). 729–734. 25 indexed citations
20.
Hijiya, Nobuko, John C. Panetta, Yinmei Zhou, et al.. (2006). Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 108(13). 3997–4002. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William E. Evans Breakdown of academic impact, for papers by Ching‐Hon Pui Breakdown of academic impact, for papers by Teri E. Klein Breakdown of academic impact, for papers by Munir Pirmohamed Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Jan H.M. Schellens Breakdown of academic impact, for papers by Alex Sparreboom Breakdown of academic impact, for papers by Charles L. Loprinzi Breakdown of academic impact, for papers by Mark J. Ratain Breakdown of academic impact, for papers by Henk‐Jan Guchelaar
Rankless by CCL
2026